1. Wen, C., & Dehnel, T. (2011). China wrestles with lung cancer. Lancet Oncology, 12(1), 15.
2. Hashizume, H., Falcón, B. L., Kuroda, T., et al. (2010). Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Research, 70(6), 2213–2223.
3. Leow, C. C., Coffman, K., Inigo, I., et al. (2012). MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. International Journal of Oncology, 40(5), 1321–1330.
4. Falcón, B. L., Hashizume, H., & Koumoutsakos, P. (2009). Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. American Journal of Pathology, 175(5), 2159–2170.
5. Bradley, D. J., leum, W. N., Purdy, J. A., et al. (2002). Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small cell lung carcinoma. International Journal of Radiation Oncology Biology Physics, 52, 47–49.